3月26日午间,康臣药业(1681.HK)发布2024全年业绩。在医药行业内外复杂环境下,公司整体表现稳健增长,展现出强大的韧性。在宏观经济不确定性延续的背景下,这份高质量成绩单再度赢得市场信任。截至4月2日收盘,公司自2024年以来股价累计涨幅达139.02%,不仅显著超越恒生指数同期表现,更大幅甩开恒生医疗保健指数涨幅,最新总市值已站稳78亿港元关口。在面对诸多挑战下,康臣药业是如何做到高质量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.